Skip to main content

A paradigm for the establishment of new prognostic markers for common cancers: protease systems as indicators of invasive potential.

Objective

A rational approach to focused adjuvant therapy is urgently needed in the management of patients suffering from the most common cancers; the ability to identify patients at high risk would enable most cost-effective use of the treatments available. This proposal assembles a collaborative effort from seven leading European cancer research laboratories to identify new prognostic marker sets based on a systematic exploration of tissue protease systems functionally involved in tumour progression. The partners will apply state of the art molecular biology to identify the most relevant novel proteases, before embarking upon their quantitative measurement in large collections of patient material. The clinical studies for assessment of prognostic significance will examine the prognostic significance of each marker and derive marker sets, which optimise prognostic power. Commercially attractive kits will be assembled for the new marker sets.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

COPENHAGEN UNIVERSITY HOSPITAL
Address
Stransboulevarden 49
2100 Koepenhagen
Denmark

Participants (6)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Rue Laurent Fries 1
67404 Illkirch Graffenstaden
KAROLINSKA INSTITUTE
Sweden
Address
9,Doktorsringen 9 A
171 77 Stockholm
UNIVERSIDAD DE OVIEDO
Spain
Address
San Francisco 1-5
33003 Oviedo
UNIVERSITA VITA-SALUTE SAN RAFFAELE
Italy
Address
Via Olgettina 58
20132 Milano
UNIVERSITE DE LIEGE*ULG
Belgium
Address
Place Du 20 Aout 7
4000 Liege
University of East Anglia
United Kingdom
Address
University Plain
NR4 7TJ Norwich